Attached files
file | filename |
---|---|
8-K - 8-K - Merck & Co., Inc. | a12-25094_18k.htm |
EX-99.1 - EX-99.1 - Merck & Co., Inc. | a12-25094_1ex99d1.htm |
Exhibit 99.2
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
|
|
2012 |
|
2011 |
|
% Change |
| ||||||||||||||||||||||||||||
|
|
1Q |
|
2Q |
|
3Q |
|
Sep YTD |
|
1Q |
|
2Q |
|
3Q |
|
Sep YTD |
|
4Q |
|
Full Year |
|
3Q |
|
Sep YTD |
| ||||||||||
Sales |
|
$ |
11,731 |
|
$ |
12,311 |
|
$ |
11,488 |
|
$ |
35,530 |
|
$ |
11,580 |
|
$ |
12,151 |
|
$ |
12,022 |
|
$ |
35,753 |
|
$ |
12,294 |
|
$ |
48,047 |
|
-4 |
% |
-1 |
% |
Costs, Expenses and Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Materials and production |
|
4,037 |
|
4,112 |
|
4,137 |
|
12,286 |
|
4,059 |
|
4,284 |
|
4,352 |
|
12,695 |
|
4,176 |
|
16,871 |
|
-5 |
% |
-3 |
% | ||||||||||
Marketing and administrative |
|
3,074 |
|
3,249 |
|
3,063 |
|
9,386 |
|
3,164 |
|
3,525 |
|
3,340 |
|
10,029 |
|
3,704 |
|
13,733 |
|
-8 |
% |
-6 |
% | ||||||||||
Research and development |
|
1,862 |
|
2,165 |
|
1,918 |
|
5,944 |
|
2,158 |
|
1,936 |
|
1,954 |
|
6,048 |
|
2,419 |
|
8,467 |
|
-2 |
% |
-2 |
% | ||||||||||
Restructuring costs |
|
219 |
|
144 |
|
110 |
|
473 |
|
(14 |
) |
668 |
|
119 |
|
773 |
|
533 |
|
1,306 |
|
-8 |
% |
-39 |
% | ||||||||||
Equity income from affiliates |
|
(110 |
) |
(142 |
) |
(158 |
) |
(410 |
) |
(138 |
) |
(55 |
) |
(161 |
) |
(354 |
) |
(257 |
) |
(610 |
) |
-2 |
% |
16 |
% | ||||||||||
Other (income) expense, net |
|
142 |
|
103 |
|
200 |
|
446 |
|
622 |
|
121 |
|
66 |
|
809 |
|
139 |
|
946 |
|
* |
|
-45 |
% | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Income Before Taxes |
|
2,507 |
|
2,680 |
|
2,218 |
|
7,405 |
|
1,729 |
|
1,672 |
|
2,352 |
|
5,753 |
|
1,580 |
|
7,334 |
|
-6 |
% |
29 |
% | ||||||||||
Income Tax Provision (Benefit) |
|
740 |
|
860 |
|
455 |
|
2,055 |
|
658 |
|
(382 |
) |
628 |
|
904 |
|
37 |
|
942 |
|
|
|
|
| ||||||||||
Net Income |
|
1,767 |
|
1,820 |
|
1,763 |
|
5,350 |
|
1,071 |
|
2,054 |
|
1,724 |
|
4,849 |
|
1,543 |
|
6,392 |
|
2 |
% |
10 |
% | ||||||||||
Less: Net Income Attributable to Noncontrolling Interests |
|
29 |
|
27 |
|
34 |
|
89 |
|
28 |
|
30 |
|
32 |
|
89 |
|
31 |
|
120 |
|
|
|
|
| ||||||||||
Net Income Attributable to Merck & Co., Inc. |
|
$ |
1,738 |
|
$ |
1,793 |
|
$ |
1,729 |
|
$ |
5,261 |
|
$ |
1,043 |
|
$ |
2,024 |
|
$ |
1,692 |
|
$ |
4,760 |
|
$ |
1,512 |
|
$ |
6,272 |
|
2 |
% |
11 |
% |
Earnings per Common Share Assuming Dilution |
|
$ |
0.56 |
|
$ |
0.58 |
|
$ |
0.56 |
|
$ |
1.71 |
|
$ |
0.34 |
|
$ |
0.65 |
|
$ |
0.55 |
|
$ |
1.53 |
|
$ |
0.49 |
|
$ |
2.02 |
|
2 |
% |
12 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average Shares Outstanding Assuming Dilution |
|
3,074 |
|
3,072 |
|
3,079 |
|
3,077 |
|
3,104 |
|
3,110 |
|
3,091 |
|
3,102 |
|
3,069 |
|
3,094 |
|
|
|
|
| ||||||||||
Tax Rate |
|
29.5 |
% |
32.1 |
% |
20.5 |
% |
27.8 |
% |
38.1 |
% |
-22.8 |
% |
26.7 |
% |
15.7 |
% |
2.3 |
% |
12.8 |
% |
|
|
|
|
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
*100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c
|
|
GAAP |
|
Acquisition- |
|
Restructuring |
|
Certain Other |
|
Adjustment |
|
Non-GAAP |
| |||
Sales |
|
$ |
12,022 |
|
|
|
|
|
|
|
$ |
|
|
$ |
12,022 |
|
Costs, Expenses and Other |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Materials and production |
|
4,352 |
|
1,284 |
|
99 |
|
|
|
1,383 |
|
2,969 |
| |||
Marketing and administrative |
|
3,340 |
|
57 |
|
31 |
|
|
|
88 |
|
3,252 |
| |||
Research and development |
|
1,954 |
|
22 |
|
28 |
|
|
|
50 |
|
1,904 |
| |||
Restructuring costs |
|
119 |
|
|
|
119 |
|
|
|
119 |
|
|
| |||
Equity income from affiliates |
|
(161 |
) |
|
|
|
|
|
|
|
|
(161 |
) | |||
Other (income) expense, net |
|
66 |
|
|
|
|
|
(137 |
) |
(137 |
) |
203 |
| |||
Income Before Taxes |
|
2,352 |
|
(1,363 |
) |
(277 |
) |
137 |
|
(1,503 |
) |
3,855 |
| |||
Taxes on Income |
|
628 |
|
|
|
|
|
|
|
(287 |
)(4) |
915 |
| |||
Net Income |
|
1,724 |
|
|
|
|
|
|
|
(1,216 |
) |
2,940 |
| |||
Less: Net Income Attributable to Noncontrolling Interests |
|
32 |
|
|
|
|
|
|
|
|
|
32 |
| |||
Net Income Attributable to Merck & Co., Inc. |
|
$ |
1,692 |
|
|
|
|
|
|
|
$ |
(1,216 |
) |
$ |
2,908 |
|
Earnings per Common Share Assuming Dilution |
|
$ |
0.55 |
|
|
|
|
|
|
|
|
|
$ |
0.94 |
(5) | |
Average Shares Outstanding Assuming Dilution |
|
3,091 |
|
|
|
|
|
|
|
|
|
3,091 |
| |||
Tax Rate |
|
26.7 |
% |
|
|
|
|
|
|
|
|
23.7 |
% |
Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors understanding of the companys performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.
(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the companys formal restructuring programs. Amounts included in research and development expenses represent in-process research and development (IPR&D) impairment charges.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the companys formal restructuring programs.
(3) Reflects the gain on the divestiture of the companys interest in the Johnson & JohnsonºMerck Consumer Pharmaceuticals Company joint venture.
(4) Represent the estimated tax impact on the reconciling items.
(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,903 million for the third quarter of 2011.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2d
|
|
GAAP |
|
Acquisition- |
|
Restructuring |
|
Certain Other |
|
Adjustment |
|
Non-GAAP |
| |||
Sales |
|
$ |
35,753 |
|
|
|
|
|
|
|
$ |
|
|
$ |
35,753 |
|
Costs, Expenses and Other |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Materials and production |
|
12,695 |
|
3,925 |
|
280 |
|
|
|
4,205 |
|
8,490 |
| |||
Marketing and administrative |
|
10,029 |
|
192 |
|
77 |
|
|
|
269 |
|
9,760 |
| |||
Research and development |
|
6,048 |
|
343 |
|
89 |
|
|
|
432 |
|
5,616 |
| |||
Restructuring costs |
|
773 |
|
|
|
773 |
|
|
|
773 |
|
|
| |||
Equity income from affiliates |
|
(354 |
) |
|
|
|
|
|
|
|
|
(354 |
) | |||
Other (income) expense, net |
|
809 |
|
|
|
|
|
236 |
|
236 |
|
573 |
| |||
Income Before Taxes |
|
5,753 |
|
(4,460 |
) |
(1,219 |
) |
(236 |
) |
(5,915 |
) |
11,668 |
| |||
Taxes on Income |
|
904 |
|
|
|
|
|
|
|
(1,955 |
)(4) |
2,859 |
| |||
Net Income |
|
4,849 |
|
|
|
|
|
|
|
(3,960 |
) |
8,809 |
| |||
Less: Net Income Attributable to Noncontrolling Interests |
|
89 |
|
|
|
|
|
|
|
|
|
89 |
| |||
Net Income Attributable to Merck & Co., Inc. |
|
$ |
4,760 |
|
|
|
|
|
|
|
$ |
(3,960 |
) |
$ |
8,720 |
|
Earnings per Common Share Assuming Dilution |
|
$ |
1.53 |
|
|
|
|
|
|
|
|
|
$ |
2.80 |
(5) | |
Average Shares Outstanding Assuming Dilution |
|
3,102 |
|
|
|
|
|
|
|
|
|
3,102 |
| |||
Tax Rate |
|
15.7 |
% |
|
|
|
|
|
|
|
|
24.5 |
% |
Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors understanding of the companys performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.
(1) Amounts included in materials and production costs reflect expenses of $3.8 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as $118 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the companys formal restructuring programs. Amounts included in research and development expenses represent in-process research and development (IPR&D) impairment charges.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the companys formal restructuring programs.
(3) Included in other (income) expense, net is a $500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson, a $136 million gain on the divestiture of the companys interest in the Johnson & JohnsonºMerck Consumer Pharmaceuticals Company joint venture and a $127 million gain on the sale of certain manufacturing facilities and related assets.
(4) Includes a net benefit of approximately $700 million relating to the settlement of the companys 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.
(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $8,697 million for the first nine months of 2011.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2012
(AMOUNTS IN MILLIONS)
Table 3a
|
|
Global |
|
U.S. |
|
International |
| ||||||||||||||||||
|
|
3Q12 |
|
3Q11 |
|
% Change |
|
3Q12 |
|
3Q11 |
|
% Change |
|
3Q12 |
|
3Q11 |
|
% Change |
| ||||||
TOTAL SALES (1) |
|
$ |
11,488 |
|
$ |
12,022 |
|
-4 |
|
$ |
5,112 |
|
$ |
5,345 |
|
-4 |
|
$ |
6,377 |
|
$ |
6,677 |
|
-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
PHARMACEUTICAL |
|
9,875 |
|
10,354 |
|
-5 |
|
4,304 |
|
4,515 |
|
-5 |
|
5,571 |
|
5,839 |
|
-5 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Primary Care and Womens Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cardiovascular |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Zetia |
|
645 |
|
614 |
|
5 |
|
348 |
|
306 |
|
14 |
|
297 |
|
308 |
|
-4 |
| ||||||
Vytorin |
|
423 |
|
469 |
|
-10 |
|
193 |
|
213 |
|
-9 |
|
229 |
|
256 |
|
-10 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Diabetes & Obesity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Januvia |
|
975 |
|
846 |
|
15 |
|
546 |
|
473 |
|
15 |
|
429 |
|
373 |
|
15 |
| ||||||
Janumet |
|
405 |
|
350 |
|
16 |
|
216 |
|
183 |
|
18 |
|
189 |
|
167 |
|
13 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Respiratory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Singulair |
|
602 |
|
1,336 |
|
-55 |
|
249 |
|
901 |
|
-72 |
|
353 |
|
435 |
|
-19 |
| ||||||
Nasonex |
|
292 |
|
266 |
|
10 |
|
156 |
|
135 |
|
15 |
|
136 |
|
130 |
|
4 |
| ||||||
Clarinex |
|
64 |
|
128 |
|
-50 |
|
17 |
|
46 |
|
-62 |
|
46 |
|
82 |
|
-43 |
| ||||||
Asmanex |
|
42 |
|
42 |
|
|
|
38 |
|
38 |
|
1 |
|
4 |
|
4 |
|
-15 |
| ||||||
Dulera |
|
52 |
|
22 |
|
* |
|
50 |
|
22 |
|
* |
|
2 |
|
|
|
* |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Womens Health & Endocrine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Fosamax |
|
152 |
|
215 |
|
-29 |
|
6 |
|
10 |
|
-38 |
|
146 |
|
205 |
|
-29 |
| ||||||
NuvaRing |
|
156 |
|
159 |
|
-2 |
|
93 |
|
90 |
|
3 |
|
64 |
|
68 |
|
-7 |
| ||||||
Follistim AQ |
|
111 |
|
129 |
|
-14 |
|
39 |
|
45 |
|
-14 |
|
72 |
|
84 |
|
-14 |
| ||||||
Implanon |
|
93 |
|
80 |
|
16 |
|
34 |
|
34 |
|
-1 |
|
59 |
|
45 |
|
30 |
| ||||||
Cerazette |
|
64 |
|
74 |
|
-14 |
|
|
|
|
|
|
|
64 |
|
74 |
|
-14 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Maxalt |
|
166 |
|
156 |
|
7 |
|
136 |
|
105 |
|
30 |
|
31 |
|
51 |
|
-40 |
| ||||||
Arcoxia |
|
109 |
|
108 |
|
2 |
|
|
|
|
|
|
|
109 |
|
108 |
|
2 |
| ||||||
Avelox |
|
30 |
|
59 |
|
-50 |
|
27 |
|
49 |
|
-44 |
|
2 |
|
10 |
|
-80 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Hospital and Specialty |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Immunology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Remicade |
|
490 |
|
561 |
|
-13 |
|
|
|
|
|
|
|
490 |
|
561 |
|
-13 |
| ||||||
Simponi |
|
86 |
|
74 |
|
15 |
|
|
|
|
|
|
|
86 |
|
74 |
|
15 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Infectious Disease |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Isentress |
|
399 |
|
343 |
|
16 |
|
219 |
|
168 |
|
31 |
|
180 |
|
175 |
|
3 |
| ||||||
PegIntron |
|
165 |
|
163 |
|
1 |
|
22 |
|
19 |
|
19 |
|
143 |
|
144 |
|
-1 |
| ||||||
Cancidas |
|
163 |
|
150 |
|
8 |
|
8 |
|
14 |
|
-41 |
|
155 |
|
136 |
|
13 |
| ||||||
Victrelis |
|
149 |
|
31 |
|
* |
|
79 |
|
21 |
|
* |
|
70 |
|
10 |
|
* |
| ||||||
Invanz |
|
118 |
|
107 |
|
10 |
|
60 |
|
55 |
|
10 |
|
58 |
|
52 |
|
11 |
| ||||||
Primaxin |
|
109 |
|
124 |
|
-12 |
|
6 |
|
21 |
|
-70 |
|
103 |
|
103 |
|
-1 |
| ||||||
Noxafil |
|
66 |
|
61 |
|
9 |
|
19 |
|
17 |
|
12 |
|
47 |
|
44 |
|
7 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Oncology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Temodar |
|
227 |
|
223 |
|
2 |
|
111 |
|
100 |
|
11 |
|
116 |
|
123 |
|
-6 |
| ||||||
Emend |
|
111 |
|
98 |
|
12 |
|
67 |
|
60 |
|
11 |
|
44 |
|
38 |
|
14 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cosopt / Trusopt |
|
102 |
|
124 |
|
-18 |
|
3 |
|
4 |
|
-22 |
|
99 |
|
121 |
|
-18 |
| ||||||
Bridion |
|
68 |
|
52 |
|
29 |
|
|
|
|
|
|
|
68 |
|
52 |
|
29 |
| ||||||
Integrilin |
|
48 |
|
53 |
|
-9 |
|
44 |
|
47 |
|
-7 |
|
4 |
|
5 |
|
-28 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Diversified Brands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cozaar / Hyzaar |
|
295 |
|
404 |
|
-27 |
|
3 |
|
36 |
|
-92 |
|
292 |
|
368 |
|
-21 |
| ||||||
Propecia |
|
104 |
|
112 |
|
-7 |
|
30 |
|
33 |
|
-9 |
|
74 |
|
78 |
|
-6 |
| ||||||
Zocor |
|
86 |
|
110 |
|
-22 |
|
7 |
|
7 |
|
-10 |
|
79 |
|
103 |
|
-23 |
| ||||||
Claritin Rx |
|
47 |
|
55 |
|
-14 |
|
|
|
|
|
|
|
47 |
|
55 |
|
-14 |
| ||||||
Remeron |
|
52 |
|
65 |
|
-19 |
|
1 |
|
1 |
|
-34 |
|
51 |
|
63 |
|
-19 |
| ||||||
Proscar |
|
55 |
|
58 |
|
-6 |
|
1 |
|
1 |
|
-29 |
|
54 |
|
56 |
|
-5 |
| ||||||
Vasotec / Vaseretic |
|
42 |
|
57 |
|
-27 |
|
|
|
|
|
|
|
42 |
|
57 |
|
-27 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Vaccines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Gardasil |
|
581 |
|
445 |
|
31 |
|
412 |
|
330 |
|
25 |
|
169 |
|
115 |
|
46 |
| ||||||
ProQuad, M-M-R II and Varivax |
|
396 |
|
391 |
|
1 |
|
366 |
|
369 |
|
-1 |
|
29 |
|
22 |
|
33 |
| ||||||
RotaTeq |
|
150 |
|
184 |
|
-19 |
|
108 |
|
133 |
|
-19 |
|
41 |
|
51 |
|
-19 |
| ||||||
Zostavax |
|
202 |
|
108 |
|
87 |
|
191 |
|
105 |
|
83 |
|
10 |
|
4 |
|
* |
| ||||||
Pneumovax |
|
160 |
|
133 |
|
20 |
|
139 |
|
107 |
|
30 |
|
21 |
|
26 |
|
-21 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other Pharmaceutical (2) |
|
1,023 |
|
1,015 |
|
1 |
|
258 |
|
217 |
|
19 |
|
767 |
|
798 |
|
-4 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
ANIMAL HEALTH |
|
815 |
|
826 |
|
-1 |
|
211 |
|
194 |
|
9 |
|
604 |
|
631 |
|
-4 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
CONSUMER CARE |
|
451 |
|
421 |
|
7 |
|
290 |
|
265 |
|
10 |
|
161 |
|
156 |
|
3 |
| ||||||
Claritin OTC |
|
118 |
|
118 |
|
|
|
81 |
|
79 |
|
2 |
|
37 |
|
39 |
|
-5 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other Revenues (3) |
|
347 |
|
421 |
|
-17 |
|
306 |
|
370 |
|
-17 |
|
41 |
|
50 |
|
-18 |
| ||||||
Astra |
|
255 |
|
299 |
|
-15 |
|
255 |
|
299 |
|
-15 |
|
|
|
|
|
|
| ||||||
* 100% or greater
(1) Only select products are shown.
(2) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $116 million and $100 million on a global basis for third quarter 2012 and 2011, respectively.
(3) Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2012
(AMOUNTS IN MILLIONS)
Table 3b
|
|
Global |
|
U.S. |
|
International |
| ||||||||||||||||||
|
|
Sep |
|
Sep |
|
% Change |
|
Sep |
|
Sep |
|
% Change |
|
Sep |
|
Sep |
|
% Change |
| ||||||
TOTAL SALES (1) |
|
$ |
35,530 |
|
$ |
35,753 |
|
-1 |
|
$ |
15,676 |
|
$ |
15,199 |
|
3 |
|
$ |
19,853 |
|
$ |
20,554 |
|
-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
PHARMACEUTICAL |
|
30,517 |
|
30,534 |
|
|
|
13,127 |
|
12,511 |
|
5 |
|
17,390 |
|
18,023 |
|
-4 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Primary Care and Womens Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cardiovascular |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Zetia |
|
1,891 |
|
1,788 |
|
6 |
|
987 |
|
896 |
|
10 |
|
904 |
|
892 |
|
1 |
| ||||||
Vytorin |
|
1,312 |
|
1,407 |
|
-7 |
|
578 |
|
675 |
|
-14 |
|
734 |
|
733 |
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Diabetes & Obesity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Januvia |
|
2,952 |
|
2,364 |
|
25 |
|
1,571 |
|
1,322 |
|
19 |
|
1,382 |
|
1,042 |
|
33 |
| ||||||
Janumet |
|
1,207 |
|
977 |
|
24 |
|
628 |
|
518 |
|
21 |
|
580 |
|
458 |
|
27 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Respiratory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Singulair |
|
3,373 |
|
4,018 |
|
-16 |
|
2,127 |
|
2,579 |
|
-18 |
|
1,245 |
|
1,439 |
|
-13 |
| ||||||
Nasonex |
|
960 |
|
962 |
|
|
|
459 |
|
440 |
|
4 |
|
501 |
|
521 |
|
-4 |
| ||||||
Clarinex |
|
337 |
|
492 |
|
-32 |
|
122 |
|
146 |
|
-16 |
|
215 |
|
347 |
|
-38 |
| ||||||
Asmanex |
|
141 |
|
149 |
|
-6 |
|
128 |
|
134 |
|
-5 |
|
13 |
|
15 |
|
-11 |
| ||||||
Dulera |
|
140 |
|
59 |
|
* |
|
135 |
|
58 |
|
* |
|
6 |
|
1 |
|
* |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Womens Health & Endocrine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Fosamax |
|
522 |
|
644 |
|
-19 |
|
22 |
|
38 |
|
-41 |
|
500 |
|
606 |
|
-18 |
| ||||||
NuvaRing |
|
459 |
|
455 |
|
1 |
|
268 |
|
267 |
|
|
|
191 |
|
188 |
|
1 |
| ||||||
Follistim AQ |
|
352 |
|
404 |
|
-13 |
|
124 |
|
121 |
|
2 |
|
228 |
|
283 |
|
-19 |
| ||||||
Implanon |
|
254 |
|
220 |
|
15 |
|
104 |
|
92 |
|
13 |
|
150 |
|
128 |
|
17 |
| ||||||
Cerazette |
|
202 |
|
199 |
|
2 |
|
|
|
|
|
|
|
202 |
|
199 |
|
2 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Maxalt |
|
476 |
|
460 |
|
3 |
|
363 |
|
319 |
|
14 |
|
113 |
|
141 |
|
-20 |
| ||||||
Arcoxia |
|
338 |
|
321 |
|
5 |
|
|
|
|
|
|
|
338 |
|
321 |
|
5 |
| ||||||
Avelox |
|
146 |
|
227 |
|
-35 |
|
140 |
|
201 |
|
-31 |
|
7 |
|
25 |
|
-74 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Hospital and Specialty |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Immunology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Remicade |
|
1,527 |
|
2,156 |
|
-29 |
|
|
|
|
|
|
|
1,527 |
|
2,156 |
|
-29 |
| ||||||
Simponi |
|
236 |
|
203 |
|
16 |
|
|
|
|
|
|
|
236 |
|
203 |
|
16 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Infectious Disease |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Isentress |
|
1,133 |
|
972 |
|
17 |
|
608 |
|
488 |
|
25 |
|
525 |
|
484 |
|
9 |
| ||||||
PegIntron |
|
510 |
|
482 |
|
6 |
|
79 |
|
46 |
|
71 |
|
431 |
|
436 |
|
-1 |
| ||||||
Cancidas |
|
474 |
|
476 |
|
|
|
23 |
|
32 |
|
-30 |
|
451 |
|
443 |
|
2 |
| ||||||
Victrelis |
|
387 |
|
53 |
|
* |
|
215 |
|
39 |
|
* |
|
172 |
|
14 |
|
* |
| ||||||
Invanz |
|
329 |
|
296 |
|
11 |
|
166 |
|
150 |
|
11 |
|
163 |
|
146 |
|
11 |
| ||||||
Primaxin |
|
301 |
|
397 |
|
-24 |
|
17 |
|
72 |
|
-76 |
|
284 |
|
324 |
|
-13 |
| ||||||
Noxafil |
|
191 |
|
171 |
|
12 |
|
54 |
|
44 |
|
23 |
|
136 |
|
127 |
|
8 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Oncology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Temodar |
|
688 |
|
704 |
|
-2 |
|
322 |
|
298 |
|
8 |
|
366 |
|
407 |
|
-10 |
| ||||||
Emend |
|
358 |
|
305 |
|
17 |
|
202 |
|
171 |
|
18 |
|
156 |
|
134 |
|
16 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cosopt / Trusopt |
|
331 |
|
360 |
|
-8 |
|
10 |
|
12 |
|
-18 |
|
321 |
|
348 |
|
-8 |
| ||||||
Bridion |
|
186 |
|
141 |
|
32 |
|
|
|
|
|
|
|
186 |
|
141 |
|
32 |
| ||||||
Integrilin |
|
160 |
|
172 |
|
-7 |
|
147 |
|
158 |
|
-6 |
|
13 |
|
15 |
|
-12 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Diversified Brands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Cozaar / Hyzaar |
|
969 |
|
1,236 |
|
-22 |
|
16 |
|
87 |
|
-81 |
|
953 |
|
1,149 |
|
-17 |
| ||||||
Propecia |
|
312 |
|
330 |
|
-5 |
|
95 |
|
98 |
|
-3 |
|
218 |
|
232 |
|
-6 |
| ||||||
Zocor |
|
285 |
|
345 |
|
-17 |
|
20 |
|
24 |
|
-19 |
|
265 |
|
320 |
|
-17 |
| ||||||
Claritin Rx |
|
181 |
|
240 |
|
-25 |
|
|
|
|
|
|
|
181 |
|
240 |
|
-25 |
| ||||||
Remeron |
|
175 |
|
181 |
|
-3 |
|
4 |
|
5 |
|
-24 |
|
171 |
|
176 |
|
-3 |
| ||||||
Proscar |
|
160 |
|
171 |
|
-6 |
|
3 |
|
4 |
|
-27 |
|
157 |
|
167 |
|
-6 |
| ||||||
Vasotec / Vaseretic |
|
144 |
|
173 |
|
-17 |
|
|
|
|
|
|
|
144 |
|
173 |
|
-17 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Vaccines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Gardasil |
|
1,189 |
|
935 |
|
27 |
|
809 |
|
679 |
|
19 |
|
379 |
|
256 |
|
48 |
| ||||||
ProQuad, M-M-R II and Varivax |
|
967 |
|
927 |
|
4 |
|
880 |
|
865 |
|
2 |
|
87 |
|
62 |
|
40 |
| ||||||
RotaTeq |
|
433 |
|
457 |
|
-5 |
|
317 |
|
360 |
|
-12 |
|
116 |
|
96 |
|
20 |
| ||||||
Zostavax |
|
426 |
|
254 |
|
68 |
|
396 |
|
247 |
|
60 |
|
30 |
|
7 |
|
* |
| ||||||
Pneumovax |
|
372 |
|
276 |
|
35 |
|
297 |
|
214 |
|
39 |
|
76 |
|
62 |
|
22 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other Pharmaceutical (2) |
|
3,031 |
|
2,975 |
|
2 |
|
691 |
|
612 |
|
13 |
|
2,337 |
|
2,361 |
|
-1 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
ANIMAL HEALTH |
|
2,501 |
|
2,385 |
|
5 |
|
643 |
|
519 |
|
24 |
|
1,859 |
|
1,867 |
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
CONSUMER CARE |
|
1,557 |
|
1,479 |
|
5 |
|
1,056 |
|
986 |
|
7 |
|
501 |
|
493 |
|
2 |
| ||||||
Claritin OTC |
|
432 |
|
419 |
|
3 |
|
318 |
|
304 |
|
5 |
|
114 |
|
115 |
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Other Revenues (3) |
|
955 |
|
1,355 |
|
-30 |
|
851 |
|
1,184 |
|
-28 |
|
104 |
|
172 |
|
-39 |
| ||||||
Astra |
|
664 |
|
928 |
|
-28 |
|
664 |
|
928 |
|
-28 |
|
|
|
|
|
|
| ||||||
* 100% or greater
(1) Only select products are shown.
(2) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $251 million and $221 million on a global basis for September YTD 2012 and 2011, respectively.
(3) Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
Table 3c
|
|
1Q12 |
|
2Q12 |
|
3Q12 |
|
Sep |
|
1Q11 |
|
2Q11 |
|
3Q11 |
|
Sep |
|
4Q11 |
|
Full Year |
|
% |
|
% |
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
TOTAL PHARMACEUTICAL |
|
$ |
10,082 |
|
$ |
10,560 |
|
$ |
9,875 |
|
$ |
30,517 |
|
$ |
9,820 |
|
$ |
10,360 |
|
$ |
10,354 |
|
$ |
30,534 |
|
$ |
10,755 |
|
$ |
41,289 |
|
-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
United States |
|
4,189 |
|
4,633 |
|
4,304 |
|
13,127 |
|
3,907 |
|
4,088 |
|
4,515 |
|
12,511 |
|
4,606 |
|
17,117 |
|
-5 |
|
5 |
| ||||||||||
% Pharmaceutical Sales |
|
41.6 |
% |
43.9 |
% |
43.6 |
% |
43.0 |
% |
39.8 |
% |
39.5 |
% |
43.6 |
% |
41.0 |
% |
42.8 |
% |
41.5 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Europe (1) |
|
2,558 |
|
2,540 |
|
2,210 |
|
7,309 |
|
2,587 |
|
2,827 |
|
2,588 |
|
8,002 |
|
2,621 |
|
10,623 |
|
-15 |
|
-9 |
| ||||||||||
% Pharmaceutical Sales |
|
25.4 |
% |
24.1 |
% |
22.4 |
% |
24.0 |
% |
26.3 |
% |
27.3 |
% |
25.0 |
% |
26.2 |
% |
24.4 |
% |
25.7 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Japan |
|
1,267 |
|
1,199 |
|
1,124 |
|
3,590 |
|
1,164 |
|
1,104 |
|
1,114 |
|
3,382 |
|
1,327 |
|
4,709 |
|
1 |
|
6 |
| ||||||||||
% Pharmaceutical Sales |
|
12.6 |
% |
11.4 |
% |
11.4 |
% |
11.8 |
% |
11.8 |
% |
10.7 |
% |
10.8 |
% |
11.1 |
% |
12.3 |
% |
11.4 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Latin America |
|
627 |
|
668 |
|
715 |
|
2,010 |
|
700 |
|
743 |
|
667 |
|
2,109 |
|
747 |
|
2,857 |
|
7 |
|
-5 |
| ||||||||||
% Pharmaceutical Sales |
|
6.2 |
% |
6.3 |
% |
7.2 |
% |
6.6 |
% |
7.1 |
% |
7.2 |
% |
6.4 |
% |
6.9 |
% |
6.9 |
% |
6.9 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Asia Pacific |
|
762 |
|
787 |
|
846 |
|
2,394 |
|
699 |
|
779 |
|
763 |
|
2,241 |
|
736 |
|
2,977 |
|
11 |
|
7 |
| ||||||||||
% Pharmaceutical Sales |
|
7.6 |
% |
7.4 |
% |
8.6 |
% |
7.8 |
% |
7.1 |
% |
7.5 |
% |
7.4 |
% |
7.3 |
% |
6.8 |
% |
7.2 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
China |
|
221 |
|
262 |
|
262 |
|
746 |
|
187 |
|
206 |
|
220 |
|
613 |
|
221 |
|
834 |
|
19 |
|
22 |
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Eastern Europe/Middle East Africa |
|
361 |
|
441 |
|
366 |
|
1,168 |
|
358 |
|
369 |
|
371 |
|
1,097 |
|
378 |
|
1,476 |
|
-1 |
|
6 |
| ||||||||||
% Pharmaceutical Sales |
|
3.6 |
% |
4.2 |
% |
3.7 |
% |
3.8 |
% |
3.6 |
% |
3.6 |
% |
3.6 |
% |
3.6 |
% |
3.5 |
% |
3.6 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Canada |
|
264 |
|
236 |
|
257 |
|
758 |
|
360 |
|
399 |
|
285 |
|
1,044 |
|
279 |
|
1,323 |
|
-10 |
|
-27 |
| ||||||||||
% Pharmaceutical Sales |
|
2.6 |
% |
2.2 |
% |
2.6 |
% |
2.5 |
% |
3.7 |
% |
3.9 |
% |
2.8 |
% |
3.4 |
% |
2.6 |
% |
3.2 |
% |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Other |
|
53 |
|
56 |
|
52 |
|
161 |
|
45 |
|
51 |
|
51 |
|
147 |
|
61 |
|
208 |
|
2 |
|
10 |
| ||||||||||
% Pharmaceutical Sales |
|
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.5 |
% |
0.6 |
% |
0.5 |
% |
|
|
|
| ||||||||||
(1) Europe primarily represents all European Union countries and the European Union accession markets.
MERCK & CO., INC.
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP
THIRD QUARTER 2012
Table 4 |
EQUITY INCOME FROM AFFILIATES (millions of dollars)
|
|
3Q12 |
|
3Q11 |
|
YTD 2012 |
|
YTD 2011 |
| ||||
ASTRAZENECA LP |
|
$ |
134 |
|
$ |
141 |
|
$ |
387 |
|
$ |
318 |
|
Other (1) |
|
24 |
|
20 |
|
23 |
|
36 |
| ||||
TOTAL |
|
$ |
158 |
|
$ |
161 |
|
$ |
410 |
|
$ |
354 |
|
(1) Includes results for Sanofi Pasteur MSD.
|
SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL (millions of dollars)
All sales reported here are end-market JV sales, presented on a NET basis.
|
|
3Q12 |
|
3Q11 |
|
YTD 2012 |
|
YTD 2011 |
| ||||
GARDASIL |
|
$ |
82 |
|
$ |
59 |
|
$ |
197 |
|
$ |
183 |
|
FLU VACCINES |
|
82 |
|
128 |
|
82 |
|
129 |
| ||||
OTHER VIRAL VACCINES |
|
26 |
|
29 |
|
81 |
|
77 |
| ||||
ROTATEQ |
|
12 |
|
12 |
|
35 |
|
32 |
| ||||
HEPATITIS VACCINES |
|
7 |
|
9 |
|
24 |
|
29 |
| ||||
Other Vaccines |
|
127 |
|
138 |
|
352 |
|
355 |
| ||||
TOTAL SANOFI PASTEUR MSD SALES |
|
$ |
336 |
|
$ |
375 |
|
$ |
771 |
|
$ |
805 |
|
|
OTHER (INCOME) EXPENSE, NET (millions of dollars)
|
|
3Q12 |
|
3Q11 |
|
YTD 2012 |
|
YTD 2011 |
| ||||
INTEREST INCOME (1) |
|
$ |
(47 |
) |
$ |
(32 |
) |
$ |
(177 |
) |
$ |
(102 |
) |
INTEREST EXPENSE (1) |
|
178 |
|
176 |
|
524 |
|
522 |
| ||||
EXCHANGE LOSSES |
|
50 |
|
59 |
|
130 |
|
102 |
| ||||
Other, net (2) |
|
19 |
|
(137 |
) |
(31 |
) |
287 |
| ||||
TOTAL |
|
$ |
200 |
|
$ |
66 |
|
$ |
446 |
|
$ |
809 |
|
(1) Prior period amounts reflect reclassifications to conform to the current period presentation.
(2) Other, net in the first nine months of 2011 includes a charge of $500 million related to the resolution of the arbitration proceeding with Johnson & Johnson.
|